4.6 Article

Dementia in Parkinson's Disease: Usefulness of the Pill Questionnaire

Journal

MOVEMENT DISORDERS
Volume 28, Issue 13, Pages 1832-1837

Publisher

WILEY
DOI: 10.1002/mds.25649

Keywords

Parkinson's disease; dementia; Pill Questionnaire; screening; activities of daily living

Funding

  1. UCB Pharma, Madrid, Spain

Ask authors/readers for more resources

The Level I algorithm for the diagnosis of dementia associated with Parkinson's disease (PD-D) recommended by the Movement Disorder Society task force includes a Pill Questionnaire to determine the impact of cognitive decline on daily activities. The objective of this study was to test the performance of the Pill Questionnaire as a screening tool for the detection of dementia (all-cause) in patients with PD and to test the performance of another functional scale substituting the Pill Questionnaire for the diagnosis of probable PD-D (pPD-D). Data were collected from 529 patients who had PD in Hoehn and Yahr stages 1 through 5. The measures used include the Scales for Outcomes in PD-Motor (SCOPA-Motor), scales for psychiatric complications, the Mini Mental State Examination, the Clinical Impression of Severity Index, and the Pill Questionnaire. The SCOPA-Motor functional subscale score was categorized as impact or no impact of PD on daily activities. According to clinical judgment, 13.3% of patients had dementia. For detecting dementia, the Pill Questionnaire had 89% accuracy, although its positive predictive value was 55%. Performance was worse with the categorized SCOPA-Motor subscale. According to the Movement Disorder Society task force criterion, 85 patients (16.1%) had pPD-D. When the Pill Questionnaire was substituted by the categorized SCOPA-Motor subscale, the modified algorithm showed sensitivity, specificity, and accuracy indexes over 90% but had positive predictive value of 66% for pPD-D diagnosis. Although the Pill Questionnaire demonstrated acceptable basic properties as a screening tool for dementia, its positive predictive value was low. The SCOPA-Motor subscale cannot be proposed as a substitute for the Pill Questionnaire. (c) 2013 International Parkinson and Movement Disorder Society

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Clinical Neurology

The Non-Motor Symptoms Scale in Parkinson's disease: Validation and use

Daniel J. van Wamelen, Pablo Martinez-Martin, Daniel Weintraub, Anette Schrag, Angelo Antonini, Cristian Falup-Pecurariu, Per Odin, Kallol Ray Chaudhuri

Summary: The NMSS, developed in 2007, is the first instrument for comprehensively assessing a range of non-motor symptoms in Parkinson's disease. Over the past 13 years, it has been extensively validated and utilized in over 100 clinical studies, showing strong correlations with health-related quality of life measures. The scale has proven capable of detecting longitudinal changes in non-motor symptoms and has become a key outcome measure in several randomized clinical trials.

ACTA NEUROLOGICA SCANDINAVICA (2021)

Article Clinical Neurology

Validation of the Finnish Version of the Unified Dyskinesia Rating Scale

Valtteri Kaasinen, Filip Scheperjans, Mikko Karppa, Jaana Korpela, Anna Bruck, Jussi O. T. Sipila, Juho Joutsa, Juha Jarvela, Johanna Eerola-Rautio, Mika H. Martikainen, Katja Airaksinen, Glenn T. Stebbins, Pablo Martinez-Martin, Christopher G. Goetz, Jeffrey Lin, Sheng Luo, Eero Pekkonen

Summary: The study validated the Finnish version of UDysRS and identified subtle differences compared to the reference standard, possibly related to sample composition or disease status.

EUROPEAN NEUROLOGY (2021)

Article Clinical Neurology

Predictors of short-term impulsive and compulsive behaviour after subthalamic stimulation in Parkinson disease

Anna Sauerbier, Philipp Loehrer, Stefanie T. Jost, Shania Heil, Jan N. Petry-Schmelzer, Johanna Herberg, Pia Bachon, Salima Aloui, Alexandra Gronostay, Lisa Klingelhoefer, J. Carlos Baldermann, Daniel Huys, Christopher Nimsky, Michael T. Barbe, Gereon R. Fink, Pablo Martinez-Martin, K. Ray Chaudhuri, Veerle Visser-Vandewalle, Lars Timmermann, Daniel Weintraub, Haidar S. Dafsari

Summary: This study explores the effects of subthalamic nucleus-deep brain stimulation on impulsive and compulsive behaviours in patients with Parkinson's disease. Results show that patients with higher preoperative impulsive and compulsive behaviours severity and lower dopamine agonist doses have better outcomes, while those with more severe baseline attention/memory deficits may have worse outcomes. Comprehensive assessments of non-motor and motor symptoms are needed for patients undergoing STN-DBS.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2021)

Article Clinical Neurology

In vivo cholinergic basal forebrain degeneration and cognition in Parkinson's disease: Imaging results from the COPPADIS study

Michel J. Grothe, Miguel A. Labrador-Espinosa, Silvia Jesus, Daniel Macias-Garcia, Astrid Adarmes-Gomez, Fatima Carrillo, Elena Iglesias Camacho, Pablo Franco-Rosado, Florinda Roldan Lora, Juan Francisco Martin-Rodriguez, Miquel Aguilar Barbera, Pau Pastor, Sonia Escalante Arroyo, Berta Solano Vila, Anna Cots Foraster, Javier Ruiz Martinez, Francisco Carrillo Padilla, Mercedes Pueyo Morlans, Isabel Gonzalez Aramburu, Jon Infante Ceberio, Jorge Hernandez Vara, Oriol de Fabregues-Boixar, Teresa de Deus Fonticoba, Berta Pascual-Sedano, Jaime Kulisevsky, Pablo Martinez-Martin, Diego Santos-Garcia, Pablo Mir

Summary: Early cognitive deficits in PD without dementia are more closely related to structural MRI measures of CBF degeneration than hippocampal degeneration.

PARKINSONISM & RELATED DISORDERS (2021)

Article Clinical Neurology

Does the 5-2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5-2-1-positive patients in 7 countries

Irene A. Malaty, Pablo Martinez-Martin, K. Ray Chaudhuri, Per Odin, Matej Skorvanek, Joohi Jimenez-Shahed, Michael J. Soileau, Susanna Lindvall, Josefa Domingos, Sarah Jones, Ali Alobaidi, Yash J. Jalundhwala, Prasanna L. Kandukuri, Koray Onuk, Lars Bergmann, Samira Femia, Michelle Y. Lee, Jack Wright, Angelo Antonini

Summary: The 5-2-1 screening criteria has demonstrated potential as an objective tool for identifying patients with advanced Parkinson's disease (APD), who face greater clinical, humanistic, and healthcare resource utilization burden. By accurately identifying these patients, the 5-2-1 criteria can aid in timely treatment optimization for patients with suboptimal medication control.

BMC NEUROLOGY (2022)

Article Rehabilitation

Psychometric features of brief pain inventory for Parkinson's disease during medication states

Ghorban Taghizadeh, Pablo Martinez-Martin, Sayed Amir Hasan Habibi, Sepideh Goudarzi, Mahsa Meimandi, Arian Dehmiyani, Zahra Nodehi, Siavash Rostami, Naeeme Haji Alizadeh, Maryam Mehdizadeh

Summary: This study aimed to evaluate the psychometric properties of the Brief Pain Inventory (BPI) in patients with PD, and found satisfactory internal consistency and test-retest reliability. The BPI showed acceptable diagnostic accuracy for discriminating different pain levels and between PD patients and non-PD controls.

DISABILITY AND REHABILITATION (2022)

Article Clinical Neurology

Increased homocysteine levels correlate with cortical structural damage in Parkinson's disease

Federic Sampedro, Saul Martinez-Horta, Andrea Horta-Barba, Michel J. Grothe, Miguel A. Labrador-Espinosa, Silvia Jesus, Astrid Adarmes-Gomez, Fatima Carrillo, Arnau Puig-Davi, Florinda Roldan Lora, Miquel Aguilar Barbera, Pau Pastor, Sonia Escalante Arroyo, Berta Solano Vila, Anna Cots Foraster, Javier Ruiz Martinez, Francisco Carrillo Padilla, Mercedes Pueyo Morlans, Isabel Gonzalez Aramburu, Jon Infante Ceberio, Jorge Hernandez Vara, Oriol de Fabregues-Boixar, Teresa de Deus Fonticoba, Asuncion Avila, Juan Carlos Martinez-Castrillo, Helena Bejr-Kasem, Antonia Campolongo, Berta Pascual-Sedano, Pablo Martinez-Martin, Diego Santos-Garcia, Pablo Mir, Jaime Kulisevsky

Summary: This study found that blood homocysteine levels were increased in Parkinson's disease patients and were associated with cognitive performance and structural damage in the cerebral cortex.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2022)

Article Clinical Neurology

Validation of the Thai Version of the Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale

Priya Jagota, Prachaya Srivanitchapoom, Sitthi Petchrutchatachart, Surat Singmaneesakulchai, Apichart Pisarnpong, Praween Lolekha, Suwanna Setthawatcharawanich, Parnsiri Chairangsaris, Natlada Limotai, Pawut Mekawichai, Pattamon Panyakaew, Onanong Phokaewvarangkul, Jirada Sringean, Yuvadee Pitakpatapee, Nancy LaPelle, Pablo Martinez-Martin, Xuehan Ren, Sheng Luo, Glenn T. Stebbins, Christopher G. Goetz, Roongroj Bhidayasiri

Summary: This study aims to validate the Thai translation of the Movement Disorder Society-sponsored revision of the Uni-fied Parkinson's Disease Rating Scale (MDS-UPDRS). The results showed that the Thai version was validated in clinical testing, and the overall factor structure was consistent with the English version.

JOURNAL OF MOVEMENT DISORDERS (2022)

Review Clinical Neurology

Rating Scales for Medication Adherence in Parkinson's Disease: A Systematic Review for Critique and Recommendations

Michelle H. S. Tosin, Beatriz Guitton R. B. de Oliveira, Christopher G. Goetz, Donald Morisky, Victor McConvey, Matej Skorvanek, Anette Schrag, Pablo Martinez-Martin, Glenn T. Stebbins

Summary: This study critically reviewed the measurement properties of rating scales used to assess medication adherence in Parkinson's disease (PD) and made recommendations. Several scales were suggested for use, but further work is needed to resolve the issues or develop a new scale that meets all criteria.

MOVEMENT DISORDERS CLINICAL PRACTICE (2023)

Article Clinical Neurology

Impact of advanced Parkinson's disease on caregivers: an international real-world study

Pablo Martinez-Martin, Matej Skorvanek, Tove Henriksen, Susanna Lindvall, Josefa Domingos, Ali Alobaidi, Prasanna L. L. Kandukuri, Vivek S. S. Chaudhari, Apeksha B. B. Patel, Juan Carlos Parra, James Pike, Angelo Antonini

Summary: This study examines the impact of advanced Parkinson's disease (APD) on caregiver burden, quality of life (QoL), and health status. The results show that caregivers of people with APD experience a greater burden, are less satisfied with treatment, and spend more time caregiving.

JOURNAL OF NEUROLOGY (2023)

Article Clinical Neurology

Cross-Cultural Differences in Patient Perceptions of Dyskinesia in Parkinson's Disease

Valtteri Kaasinen, Sheng Luo, Pablo Martinez-Martin, Christopher G. G. Goetz, Glenn T. T. Stebbins

Summary: This study compared patient and clinician evaluations of levodopa-induced dyskinesia (LID) severity across multiple cultures in patients with Parkinson's disease (PD). The results showed that language and cultural differences influence the subjective perception of LID, which is important to consider in multinational clinical trials on dyskinesia assessment.

MOVEMENT DISORDERS (2023)

Article Clinical Neurology

Clinical Impression of Severity Index for Parkinson's Disease and Its Association to Health-Related Quality of Life

Jenny M. M. Norlin, Klas Kellerborg, Ulf Persson, Daniel Oudin Astrom, Peter Hagell, Pablo Martinez-Martin, Per Odin

Summary: This study found an association between the Clinical Impression of Severity Index for Parkinson's Disease (CISI-PD) and health-related quality of life assessments. The findings suggest that CISI-PD could be used as a basis for defining health states in future health economic models and as outcomes in managed entry agreements.

MOVEMENT DISORDERS CLINICAL PRACTICE (2023)

Review Clinical Neurology

Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals

Stefanie Jost, Marie-Ann Kaldenbach, Angelo Antonini, Pablo Martinez-Martin, Lars Timmermann, Per Odin, Regina Katzenschlager, Rupam Borgohain, Alfonso Fasano, Fabrizio Stocchi, Nobutaka Hattori, Prashanth Lingappa Kukkle, Mayela Rodriguez-Violante, Cristian Falup-Pecurariu, Sebastian Schade, Jan Niklas Petry-Schmelzer, Vinod Metta, Daniel Weintraub, Guenther J. Deuschl, Alberto J. Espay, Eng-King Tan, Roongroj Bhidayasiri, Victor S. C. Fung, Francisco Cardoso, Claudia Trenkwalder, Peter Jenner, K. S. Ray Chaudhuri, Haidar Dafsari

Summary: This study reviewed the investigations on drug therapy for Parkinson's disease since 2010 and proposed a new drug conversion formula. These conversion formulas can help us compare drug regimens across different clinical trials. The results are important for studying the pharmacological efficacy of Parkinson's disease treatments as well as other non-pharmacological interventions.

MOVEMENT DISORDERS (2023)

Meeting Abstract Clinical Neurology

Falls Predict Acute Hospitalization in Parkinson's Disease

D. Santos Garcia, T. De Deus Fonticoba, C. Cores, E. Suarez Castro, J. Hernandez Vara, S. Jesus, P. Mir Rivera, M. Cosgaya, M. Marti, P. Pastor, I. Cabo Lopez, M. Seijo, I. Legarda, B. Vives, N. Caballol, J. Ruiz Martinez, I. Croitoru, E. Cubo, J. Miranda, G. Alonso Losada, C. Labandeira, N. Lopez Ariztegui, M. Morales Casado, I. Gonzalez Aramburu, J. Infante

EUROPEAN JOURNAL OF NEUROLOGY (2021)

Article Clinical Neurology

Pilot study of a new tool to optimise dopaminergic treatment in Parkinson's disease: the OPTIMIPARK questionnaire

Jorge U. Manez-Miro, Francisco Vivancos-Matellano, John B. Wetmore, Pablo Martinez-Martin

Summary: The study developed a questionnaire (OPTIMIPARK) to assess the dopaminergic status of Parkinson's disease patients and assist clinicians in adjusting treatment. Preliminary results showed promising feasibility and agreement with clinical criteria, suggesting OPTIMIPARK may be a useful tool in clinical decision-making for PD patients.

REVISTA DE NEUROLOGIA (2021)

No Data Available